Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2025.01.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Xiao-Meng Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Ph…. Hauptthemen laut MEDLINE: Heme Oxygenase-1, Prodrugs, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 81 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Tianjin Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Platinum(II)-based antitumor drugs are widely used in clinics but limited by severe side effects and resistance. Multi-target Platinum(IV) complexes are emerging as ideal alternatives. Heme oxygenase-1 (HO-1) works as a rate-limiting step in heme degradation and is overexpressed in malignant tumors. Herein, HO-1i-based Platinum(IV) prodrugs are prepared and candidate complex 15 is further developed into self-assembled nanoparticles (15-NPs). 15 and 15-NPs significantly increase cytotoxicity, particularly in HepG2 (74.77- and 96.14-fold increases) and A549cisR (38.6- and 47.24-fold increases), while reducing toxicity towards normal cells compared to cisplatin. In vitro experiments show 15 and 15-NPs activated multiple pathways, including p38/MAPK- and MDR-related proteins, achieving multi-target synergistic chemosensitization and anti-resistance, further verified by RNA-sequencing analysis. In vivo tests demonstrate that 15 and 15-NPs efficiently inhibit tumor growth and systemic toxicity, especially 15-NPs with optimal tumor-inhibition rate and survival (80% and 100%), superior to cisplatin (40% and 50%), attributing to its extra endocytosis, EPR effect, and precisely tumor-targeted release besides the advantage of a free HO-1i-Pt(IV) prodrug. Additionally, 15 and 15-NPs distinctly regulate T-cell and macrophage functions, thereby exhibiting a chemoimmuno-combined action. This study highlights that multi-functional Platinum(IV) prodrug target-delivered to tumors via carrier-free nanoparticles may represent an effective modality for improving cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
- Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key…
- Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China; Key Laborat…
Förderung
- National Key Research and Development Program of China
- Tianjin Medical University
- National Natural Science Foundation of China
Zitieren
APA
Liu, X. M., Li, Z., Wang, X. Y., Ding, B. W., Wang, J. Q., Qiao, X., Feng, Y. K., Hao, J. H., & Xu, J. Y. (2025). Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.01.050
Vancouver
Liu XM, Li Z, Wang XY, Ding BW, Wang JQ, Qiao X, et al. Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.01.050
BibTeX
@article{Liu2025,
author = {Liu, Xiao-Meng and Li, Zhe and Wang, Xiao-Ya and Ding, Bo-Wen and Wang, Jia-Qian and Qiao, Xin and Feng, Yu-Kuan and Hao, Ji-Hui and Xu, Jing-Yuan},
title = {Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.01.050}
}
EUVIMED